Pharmacists in Chester, IL Accepting Medicare
6 Pharmacists found. Showing 1 - 6
 Mr. David E Pentland, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2206 State St, Chester, IL 62233 Phone: 618-826-4898 |
 Kathleen Ann Winkler, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1900 State St, Chester, IL 62233 Phone: 618-826-6134 |
Mrs. Andrea Winterberg, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2206 State St, Chester, IL 62233 Phone: 618-826-4898 |
Dr. Douglas Scott Cockrell, PHARMD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2206 State St, Chester, IL 62233 Phone: 618-826-4898 Fax: 618-826-3751 |
Dr. Elaine Moy, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1315 Lehmen Dr, Chester, IL 62233 Phone: 618-861-0330 Fax: 618-826-3915 |
Diane Meyerhoff, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2323 Old Plank Rd, Chester, IL 62233 Phone: 618-826-2511 Fax: 618-826-3060 |
News Archive
Scientists discover new genetic mutations causing inherited deaf-blindness
A team of scientists from Sechenov First Moscow State Medical University together with their colleagues from leading scientific centers of Moscow and India described a number of genetic mutations causing Usher syndrome (inherited deaf-blindness).
Insurer sues Medtronic over bone-growth drug
Humana Inc. alleges the device maker violated federal racketeering statutes by conspiring with prominent physicians to promote unapproved uses of the drug, reports The Wall Street Journal.
Febuxostat recommended by panel for treatment of hyperuricemia in patients with gout
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout.
Liquidia commences dosing in LIQ-001 Phase 1 trial for seasonal influenza
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
Johns Hopkins gets approval to perform HIV positive to HIV positive living donor kidney transplants
Johns Hopkins hopes to become the first hospital in the U.S. to perform HIV-positive to HIV-positive organ transplants from living donors.
› Verified 5 days ago
Pharmacists
Dentists
Counselors
Occupational Therapists
Clinical Social Workers
Psychologists